FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  	OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5	
                      	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	                      	

1. Name and Address of Reporting Person *

Todisco Joseph	2. Issuer Name and Ticker or Trading Symbol

Amneal Pharmaceuticals, Inc. [ AMRX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Executive Vice President	
(Last)         (First)         (Middle)

C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD	3. Date of Earliest Transaction (MM/DD/YYYY)

5/7/2021		
(Street)

BRIDGEWATER, NJ 08807
(City)       (State)       (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)

 	6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	
1.Title of Security
(Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code
(Instr. 8)	4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)	Price				
Class A Common Stock 	5/7/2021 	 	M	  	4441 (1)	A	 (2)	284381 	D 	 	
Class A Common Stock 	5/7/2021 	 	F	  	1562 (3)	D	$5.20 	282819 	D 	 	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)	
1. Title of Derivate Security
(Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code
(Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date	7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)	8. Price of Derivative Security
(Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Restricted Stock Units 	 (2)	5/7/2021 	 	M 	  	  	4441  	 (4)	 (4)	Class A Common Stock 	4441 	$0.00 	4442 	D 	 	

Explanation of Responses:	
(1) 	Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.	
(2) 	Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.	
(3) 	Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.	
(4) 	On May 7, 2018, the reporting person was granted 17,766 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.	

Reporting Owners	
Reporting Owner Name / Address	Relationships	
	Director	10% Owner	Officer	Other	
Todisco Joseph
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD
BRIDGEWATER, NJ 08807			Executive Vice President		

Signatures		
/s/ Meredith Cook, Attorney-in-Fact		5/11/2021	
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).	
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.	

POWER OF ATTORNEY
        Know all by these presents, that the undersigned hereby constitutes and
appoints each of (i) the
General Counsel of Amneal Pharmaceuticals, Inc., a Delaware corporation (the
"Company") and who is
currently Stephen Manzano, (ii) the Associate General Counsel of the Company and
who is currently
Meredith Cook, and (iii) the Assistant Secretary of the Company and who is
currently Guy Chayoun, signing
singly, and their respective successors (including anyone serving in such
capacities on an interim or acting
basis), with full powers of substitution, as the undersigned's true and lawful
attorney-in-fact to:
1.      prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the U.S.
Securities and Exchange Commission (the "SEC") a Form ID, including amendments
thereto, and
any other documents necessary or appropriate to obtain codes and passwords
enabling the
undersigned to make electronic filings with the SEC of reports required by
Section 16(a) of the
Securities Exchange Act of 1934 or any rule or regulation of the SEC;
2.      execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or
director of the Company, and/or 10% holder of the Company's capital stock, Forms
3, 4, and 5 and
any amendments thereto in accordance with Section 16(a) of the Securities
Exchange Act of 1934
and the rules thereunder;
3.      do and perform any and all acts for and on behalf of the undersigned which
may be necessary or
desirable to complete and execute any such Form 3, 4, or 5, complete and execute
any amendment or
amendments thereto, and timely file such form with the SEC and any stock
exchange or similar
authority; and
4.      take any other action of any type whatsoever in connection with the foregoing
which, in the opinion
of such attorney-in-fact, may be of benefit to, in the best interest of, or
legally required by, the
undersigned, it being understood that the documents executed by such
attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such
terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and
perform any and every act and thing whatsoever requisite, necessary, or proper
to be done in the exercise of
any of the rights and powers herein granted, as fully to all intents and
purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming
all that such attorney-in-fact, or such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to
be done by virtue of this power of attorney and the rights and powers herein
granted. The undersigned
acknowledges that the foregoing attorneys-in-fact, in serving in such capacity
at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to
comply with Section 16 of the Securities Exchange Act of 1934.
        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer
required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of
and transactions in securities
issued by the Company, unless earlier revoked by the undersigned in a signed
writing delivered to the
foregoing attorneys-in-fact.
        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this
8th day of April 2021.
                                                /s/ Joseph Todisco
                                                By: Joseph Todisco